O-FAR Phase II Trial results

[Guest guest]

This is an OFAR trial by Dr. G. Wierda, J.

Kipps et al

" The high CR rate (up to 50%) despite the high-risk disease

features seen in our patient population suggests that the

O-FC regimen may provide another chemoimmunotherapy option

for previously untreated patients with CLL who can tolerate

potential myelosuppression.

Adverse events were manageable, with no unexpected

toxicities, and the safety profile of O-FC appeared to be

consistent with other CD20 mAb–based chemoimmunotherapy

regimens " .

Full PDF Study:

http://bloodjournal.hematologylibrary.org/content/117/24/6450.full.pdf

or

http://tinyurl.com/3guszvw